drugset / Trial / NCT00489905

Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

NCT00489905

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.

Timeline

Start
2005-04
Primary completion
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified